Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease | MicrobiomeTrials← Back to trialsNCT07627529
Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-06Est. Completion: 2027-04
Enrollment target: 20 participants Locations- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States
Other microbiome trials you might be interested in
Parkinson's Disease
Background:
\- In deep brain stimulation (DBS), a device called a neurostimulator is placed in the chest. It is attache…
Bethesda, United StatesEst. completion Dec 1, 2030
Parkinson's Disease
Background:
\- Glial cell line-derived neurotrophic factor (GDNF) is a chemical that may help protect and strengthen br…
Bethesda, United StatesCompleted Feb 4, 2022
The goal of this clinical trial is to evaluate the efficacy and safety of an adaptive deep brain stimulation (aDBS) syst…
Hefei, ChinaEst. completion May 31, 2027